Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE
2019-003916-29Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Mar 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, carboplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall survival. Started Mar 2020; status: completed.
02
Drugs
atezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2019-003916-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003916-29.